<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435447</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-ALL-2011</org_study_id>
    <nct_id>NCT01435447</nct_id>
  </id_info>
  <brief_title>Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies</brief_title>
  <official_title>Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With Lymphoid Malignancies Undergoing Allogeienc Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic stem cell transplantation is potential curative therapy for adult lymphoid
      malignancies. Based on our previous study, the condition with iv-busulfan (iv-BU) and
      cyclophosphamide (CTX) is feasible with low toxicity and transplantation mortality and
      long-term survival is comparable to most data reported with slightly higher relapse rate
      particularly for patients in CR2. In this study, the investigators aim to further improve the
      conditioning with Fludarabine + iv-BU and to use CTX after stem cell transfusion as
      consolidation for lymphoid malignancies and graft-versus-host disease (GVHD) prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with adult lymphoid malignancies received conditioning with Fludarabine + iv-BU. The
      GVHD was consisting of D+3 and D+4 CTX after stem cell transfusion. CSA will be added for all
      patients after D+5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute graft versus host disease (GVHD)</measure>
    <time_frame>day 100</time_frame>
    <description>d100 incidence of acute GVHD, grade II-IV or grade III-IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chronic GVHD</measure>
    <time_frame>3 years</time_frame>
    <description>3-year incidence of chronic GVHD and extensive cGVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality (NRM)</measure>
    <time_frame>3 years</time_frame>
    <description>estimated 3-year NRM after transplantation (death not due to relapse disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulated incidence of relapse (CIR)</measure>
    <time_frame>3 years</time_frame>
    <description>estimated 3-year CIR after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>estimated 3-year EFS estimated 3-year EFS after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>estimated 3-year OS after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free, relapse-free survival (GRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>estimated 3-year survival for patients without relapse, without III-IV aGVHD and without cGVHD required systemic treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Lymphoid Malignancies</condition>
  <arm_group>
    <arm_group_label>FLu-Bu-Cy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLu-Bu-Cy</intervention_name>
    <description>Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.</description>
    <arm_group_label>FLu-Bu-Cy</arm_group_label>
    <other_name>Study group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult acute lymphocytic leukemia in 1st or second remission; lymphoid malignancies in
             1st or second remission

          -  age 16-60 years

          -  with inform consent

          -  no contraindication for allogeneic transplantation: active infection, allergy to
             FLu/Bu/CTX, liver and renal function damage

          -  HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related
             donor (haplo)

        Exclusion Criteria:

          -  age less than 16 years or over 60 years

          -  liver function/renal function damage (over 2 X upper normal range)

          -  with mental disease

          -  other contraindication of all-HSCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Hu, m.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood and Marrow Transplantation Center, Rui Jin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Center, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>conditioning</keyword>
  <keyword>fludarabine</keyword>
  <keyword>busulfan</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

